Studies

Cystic fibrosis (CF) is a monogenic disorder leading to pulmonary disease, pancreatic insufficiency and cystic fibrosis-related diabetes (CFRD). Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are now being investigated in people with cystic fib…

ReviewTirzepatide

PMID: 41991874

Effects of tirzepatide, a dual GIP and GLP-1 receptor agonist, on blood pressure, cardiac function, and sympathetic nervous system in stroke-prone spontaneously hypertensive rats.

Hypertension research : official journal of the Japanese Society of Hypertension|2026|Ono Y et al.

Tirzepatide, a dual agonist for glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, has shown robust efficacy in treating diabetes and obesity, and in obese patients with heart failure with preserved ejec…

Animal StudyTirzepatide

PMID: 41992025

Combination of prolonged water fasting and GLP-1 for refractory morbid obesity: Case report.

European journal of clinical nutrition|2026|Palmisano T et al.

INTRODUCTION: Water fasting involves completely abstaining from all caloric intake. Multiple studies have demonstrated that water fasting for up to 21 days is well-tolerated, but none focused on patients with severe obesity (body mass index ≥ 40) or…

Tirzepatide

PMID: 41998348

Tirzepatide therapy reduces subclinical leaflet thrombosis and paravalvular leak after transcatheter aortic valve replacement in obese patients: The TAVR-MET trial.

Cardiovascular revascularization medicine : including molecular interventions|2026|Thirugnanam A, Chandrakanth , Pruthvi

BACKGROUND: Obesity is increasingly recognized as a critical modifier of outcomes following transcatheter aortic valve replacement (TAVR), predisposing patients to subclinical leaflet thrombosis (SLT), hypo-attenuated leaflet thickening (HALT), and p…

ReviewTirzepatide

PMID: 42000295

Weight "regain" in obesity shifts responsibility from biology to personal inadequacy.

BMJ (Clinical research ed.)|2026|Kopitowski K, Franco J

Semaglutide Tirzepatide

PMID: 41974489

Impact of Semaglutide as Weight Management Medication on Clinical Parameters and Health-Related Quality of Life: A Single-Center Study from Saudi Arabia.

Healthcare (Basel, Switzerland)|2026|Dayel F et al.

Despite the cardiometabolic benefit of semaglutide, its impact on quality of life and whether patients' characteristics influence clinical outcomes and health-related quality of life (HRQoL) remain ambiguous.A retrospective review of patient charts w…

Semaglutide

PMID: 41975849

Edible Marine Red Algaas a Potential Functional Ingredient: Chemical Profiling and Metabolic Effects in Diet-Induced Obese Rats.

Foods (Basel, Switzerland)|2026|Bahtiar A et al.

Marine macroalgae are increasingly recognized as sources of bioactive compounds with potential benefits for metabolic health. This study investigated the chemical composition and metabolic effects of a 70% ethanol extract of the edible red algain a h…

Animal StudySemaglutide

PMID: 41976461

Disproportionality Analysis of Tirzepatide vs. Semaglutide and Liraglutide: System Organ Class-Level Post-Marketing Reporting Patterns in EudraVigilance.

International journal of molecular sciences|2026|Marin R et al.

Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist, introduces a mechanistically distinct approach within incretin-based therapies. While its efficacy is established, real-world…

Semaglutide Tirzepatide

PMID: 41977175

OGT Ameliorates Diabetes-Associated Cognitive Decline via Modulation of DRP1 Function and Mitochondrial Homeostasis.

Diabetes, obesity & metabolism|2026|Li T et al.

BACKGROUND: Diabetes-associated cognitive decline (DACD) is gradually gaining attention as a major complication of diabetes. However, to date, the specific molecular mechanisms underlying DACD have not been thoroughly characterized. METHODS: Db/db an…

Animal StudySemaglutide

PMID: 41979043

Glucagon-Like Peptide-1 Receptor Agonist Utilization Among Sleep Surgery Clinic Patients.

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery|2026|Kutler R et al.

OBJECTIVE: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are approved to treat obstructive sleep apnea (OSA), yet their use in an OSA population has not been characterized. This study evaluates GLP-1 RA use in patients presenting to a sleep s…

Semaglutide Tirzepatide

PMID: 41979383

Cardiovascular Outcomes with Tirzepatide in Type 2 Diabetes.

Cardiovascular Outcomes with Tirzepatide in Type 2 Diabetes.

Cardiovascular Outcomes with Tirzepatide in Type 2 Diabetes.

Cardiovascular Outcomes with Tirzepatide in Type 2 Diabetes.

Cardiovascular Outcomes with Tirzepatide in Type 2 Diabetes.

Cardiovascular Outcomes with Tirzepatide in Type 2 Diabetes. Reply.

Glucagon-Like Peptide-1 Receptor Agonists: Their Therapeutic Potential in Cystic Fibrosis.

Effects of tirzepatide, a dual GIP and GLP-1 receptor agonist, on blood pressure, cardiac function, and sympathetic nervous system in stroke-prone spontaneously hypertensive rats.

Combination of prolonged water fasting and GLP-1 for refractory morbid obesity: Case report.

Tirzepatide therapy reduces subclinical leaflet thrombosis and paravalvular leak after transcatheter aortic valve replacement in obese patients: The TAVR-MET trial.

Weight "regain" in obesity shifts responsibility from biology to personal inadequacy.

Genetic variants show link to patients losing more weight when taking Wegovy and Mounjaro.

Assessment of knowledge, attitude, and practices towards the usage of antidiabetic drugs for weight loss among Lebanese population.

Impact of Semaglutide as Weight Management Medication on Clinical Parameters and Health-Related Quality of Life: A Single-Center Study from Saudi Arabia.

Edible Marine Red Algaas a Potential Functional Ingredient: Chemical Profiling and Metabolic Effects in Diet-Induced Obese Rats.

Disproportionality Analysis of Tirzepatide vs. Semaglutide and Liraglutide: System Organ Class-Level Post-Marketing Reporting Patterns in EudraVigilance.

Comment on 'Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model-Informed Drug Development Approach'.

OGT Ameliorates Diabetes-Associated Cognitive Decline via Modulation of DRP1 Function and Mitochondrial Homeostasis.

Glucagon-Like Peptide-1 Receptor Agonist Utilization Among Sleep Surgery Clinic Patients.

Correction: Revisional Metabolic and Bariatric Surgery Versus Semaglutide: Which Strategy Has Greater Efficacy for Recurrent Weight Gain After Primary Bariatric Surgery?